Phase III IMvoke010 trial found that maintenance treatment with Tecentriq (atezolizumab) did not significantly improve ...

HNSCCs occur in the oral cavity, pharynx, hypopharynx, larynx, nasal cavity and salivary glands and comprise the seventh most ...

Researchers conducting a clinical trial of immunotherapy drugs for people with head and neck squamous cell carcinomas (HNSCCs) found that patients responded better to a combination of two ...

1 Department of Otorhinolaryngology-Head and Neck Surgery, University Hospitals Leuven, Belgium 2 Department of Medicine, Division of Gastroenterology, University Hospitals Leuven, Belgium ...

Head and neck squamous cell carcinomas responded better to a combination of two immunotherapies than to one immunotherapy ...

P, Leemans C. R. et al. Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx. EHNS- ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of ...

Journal of Nuclear Medicine May 2009, 50 (supplement 2) 580; ...

P, Leemans C. R. et al. Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx. EHNS- ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of ...

Eligible participants included those with stage III, T4, N0-2, M0 human papillomavirus (HPV)–positive oropharyngeal primary tumors, stage III or IVA HPV-negative oropharyngeal cancers, or stage III or ...